# ChronoScale Holdings Corp > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/ChronoScale Holdings Corp). ## Overview ChronoScale Holdings Corp is a U.S.-based medical robotics company focused on wearable robotic exoskeletons for rehabilitation and mobility support. Its business centers on the EksoNR, Ekso Indego Therapy, and Ekso Indego Personal device families, along with related services such as warranty coverage, repairs, and training. ## Products & services • EksoNR rehabilitation exoskeleton • Ekso Indego Therapy device • Ekso Indego Personal device • EksoCare extended warranty and support • Device servicing, repair, and loaners • Customer training and clinical support - **Enterprise Health devices** (55%) — Robotic exoskeletons sold or subscribed for clinical rehabilitation use in healthcare facilities. - **Personal Health devices** (20%) — Wearable exoskeletons used by individuals for personal mobility and rehabilitation support. - **Subscriptions and financing arrangements** (10%) — Device access arrangements sold through finance partners or subscription structures. - **Service and maintenance** (10%) — Fee-based repair, maintenance, and loaner-device services for installed products. - **Training and support** (5%) — Online and in-person training, clinical support, and portal-based device services. - EksoNR rehabilitation exoskeleton - Ekso Indego Therapy device - Ekso Indego Personal device - EksoCare extended warranty and support - Device servicing, repair, and loaners - Customer training and clinical support ## Customers The company sells primarily to healthcare providers and distributors that serve rehabilitation and mobility markets. In Enterprise Health, buyers include inpatient rehabilitation facilities, long-term acute care hospitals, skilled nursing facilities, outpatient clinics, and integrated delivery networks. In Personal Health, customers include end users and the financing partners that facilitate subscription-style access to devices. - **Enterprise Health providers** (primary) — Hospitals, IRFs, LTACHs, SNFs, and outpatient clinics buy EksoNR and Ekso Indego Therapy for rehabilitation programs. - **Integrated delivery networks** (primary) — Large provider networks buy multi-unit systems to standardize rehabilitation workflows and improve purchasing economics. - **Distributors** (primary) — Independent distributors buy and resell products in parts of EMEA and APAC, especially outside direct-sales markets. - **Personal Health users** (secondary) — Individuals and their care channels buy Ekso Indego Personal for mobility and rehabilitation support. - **Finance partners** (secondary) — Third-party financing partners purchase devices in subscription structures and contract with end customers. - Inpatient rehabilitation facilities buying devices for gait therapy - Integrated delivery networks purchasing multi-unit clinical deployments - Distributors acting as principal customers in some regions - Finance partners that fund subscription-style device access - Personal Health end users seeking mobility support - Clinicians and hospitals buying training, service, and support ## Geography The company sells across the Americas, EMEA, and APAC, with direct sales in the Americas and a mix of direct and distributor-led channels elsewhere. German-speaking countries in Europe are handled directly, while many other European and APAC markets rely on distributors, making channel execution important to growth. Foreign markets also require country-specific regulatory approvals and compliance, which affects where products can be marketed and how quickly they can scale. - **Americas** (55%) — Direct-sales-led region; share estimated from narrative emphasis. - **EMEA** (30%) — Includes direct German-speaking markets and distributor-led Europe/Middle East/Africa. - **APAC** (15%) — Asia-Pacific markets served through a mix of direct and indirect channels. - Americas are served mainly through a direct salesforce - EMEA uses direct sales in German-speaking countries - Non-German Europe relies heavily on distributors - APAC is a mix of direct and indirect channels - Foreign approvals and certification vary by country - Distributor coverage affects access and revenue growth ## Strategy The company is focused on expanding adoption of its rehabilitation and personal mobility products through clinical education, reimbursement coverage, and broader indications of use. It also uses service, training, and subscription structures to make adoption easier for customers with different capital budgets. The product roadmap includes new offerings such as Nomad, while distribution and strategic review activity add optionality to the business model. - **Expand reimbursement and coverage** (short-term) — Coverage determines affordability and adoption for Personal Health devices. - **Increase clinical adoption** (short-term) — Enterprise Health sales depend on evidence, stakeholder education, and workflow fit. - **Broaden product portfolio** (medium-term) — New devices can extend the addressable market and support future growth. - **Preserve strategic flexibility** (short-term) — A strategic transaction could reshape the business or unlock value. - Expand reimbursement coverage beyond CMS - Broaden indications of use for Personal Health products - Use clinical education to drive Enterprise Health adoption - Grow subscription and financing-based device access - Commercialize Nomad after clinical feedback - Maintain optionality through strategic transaction review ## Risks The business depends on regulatory approvals, reimbursement coverage, and adoption of a relatively early-stage technology, so commercialization can be uneven. It also relies on distributors in several markets, which creates channel concentration and compliance risk, while competition and product-development execution remain important in a fast-changing medical robotics field. - **Regulatory approval risk** [high] — Products must clear country-specific approval and compliance requirements before sale. - **Distributor concentration** [high] — Independent distributors are principal customers in several non-direct markets. - **Reimbursement and coverage risk** [high] — Personal Health growth depends on insurance coverage and reimbursement processes. - **Technology and competition risk** [medium] — Exoskeleton technology remains early-stage and competitors are developing alternatives. - **Cybersecurity risk** [medium] — The company processes sensitive data and relies on connected systems and vendors. - Regulatory approvals can delay or block market access - Reimbursement coverage affects Personal Health demand - Distributor dependence can disrupt sales in some regions - Exoskeleton competition is intensifying as the field matures - Product development may not translate into market acceptance - Cybersecurity and data handling create operational risk ## Accounting Revenue recognition is important because the company sells devices outright, through subscription-style arrangements, and with bundled service obligations. Management also relies on judgment for warranty costs, inventory valuation, fair value estimates for warrants and preferred stock, and the recoverability of deferred tax assets, all of which can materially affect reported results. - **Revenue recognition and SSP allocation** — Affects timing and mix of reported revenue - **Warranty and future service costs** — Affects gross margin and accrued liabilities - **Fair value of warrants and preferred stock** — Affects other income/expense and equity - **Inventory valuation** — Affects gross profit and working capital - **Deferred tax asset recoverability** — Affects tax assets and net income - **Lease accounting** — Affects leverage and operating costs - Device sales may include multiple performance obligations - Subscription arrangements affect timing of revenue recognition - Standalone selling prices drive allocation across bundles - Warranty reserves affect service cost and gross profit - Warrant and preferred stock valuations use unobservable inputs - Inventory and credit loss estimates affect earnings and assets --- *Last updated: 2026-07-17T23:32:29.112675+00:00*